One moment
We’re getting things ready for you.
Longevity / Energy
MOTS-C Peptide Guide
Learn more about MOTS-C, including what it is, how it works, what it has been studied for, safety considerations, and how clinician-supervised treatment works through ElliotMeds.
Prescription requires licensed-provider review. No guaranteed outcomes.
Ready to get started? View MOTS-C pricing, dosage options, and start a provider chart review on the treatment page.
View Treatment OptionsMOTS-C is a mitochondrial-derived peptide studied in metabolism, exercise physiology, and aging research. This page is educational and not medical advice.
Last updated: July 2, 2026
What Is MOTS-C?
MOTS-C is a 16-amino-acid mitochondrial-derived peptide encoded by mitochondrial DNA. It is discussed in metabolism, exercise, insulin sensitivity, and aging-related research. It is not FDA-approved for wellness, weight loss, anti-aging, or performance enhancement.
How It Works
MOTS-C is studied as a mitochondrial signaling peptide that may influence AMPK-related pathways, metabolic stress response, skeletal-muscle metabolism, insulin sensitivity, and exercise-associated adaptation in preclinical research. These mechanisms are not established as proven clinical benefits.
What It’s Studied For
Research has explored MOTS-C in metabolic homeostasis, insulin sensitivity, obesity models, exercise response, and age-related physical decline, but human clinical exposure data remain limited. It is not FDA-approved for these uses.
Regulatory Status
MOTS-C is not FDA-approved, and the FDA has identified concerns for compounded MOTS-C — including immunogenicity, peptide impurities, active-ingredient characterization, and a lack of identified human exposure data for proposed routes. Compounding availability is subject to that status.
What to Expect
Use is provider-directed only; no metabolic, energy, or longevity outcome or timeline is promised, and effects are individual and unverified. MOTS-C is not a substitute for exercise, nutrition, diabetes care, or obesity treatment.
Preferred Starting Options / Dosing Notes
Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.
Average starting option
- 5 mg
Available options
- 5 mg
- 10 mg
Provider note: Do not change dose, frequency, or route of use unless directed by your clinician.
Safety Considerations
- Human data are very limited and long-term effects unknown, with immune-reaction risk and sterility/purity concerns, and the FDA has noted a lack of sufficient human safety information.
- No peptide is "safe" without qualification.
Important note
Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.
Who Is Not a Candidate
A clinician reviews metabolic history, diabetes risk, cardiovascular status, medications, cancer history, immune status, and pregnancy status before considering MOTS-C, and may determine it is not appropriate.
How It Compares
MOTS-C is a mitochondrial-derived peptide distinct from antioxidant supports such as glutathione; both are early-evidence and not FDA-approved for these uses. None is presented as superior.
Frequently Asked Questions
Is MOTS-C FDA-approved?
No — and the FDA has flagged concerns for compounded MOTS-C.
How does it work?
It is studied as a mitochondrial signaling peptide affecting metabolic pathways, in preclinical research.
What are the benefits?
Research interest is in metabolism and exercise physiology, but human evidence is limited and no benefit is guaranteed.
What are the risks?
Limited human data, immune-reaction and purity concerns, and unknown long-term safety.
Does payment guarantee a prescription?
No — a licensed clinician decides.
References
- Peer-reviewed preclinical/early-human literature on MOTS-C (PubMed)
- FDA compounding-safety communications
Disclaimer
Although the information on this page is based on available educational research and product information, it is provided for informational purposes only and is not medical advice. Treatment decisions, medication selection, dosing, and eligibility are determined by a licensed clinician after review. Not all patients are candidates, and individual results may vary. Use medications only as directed by your clinician.
Continue learning
Next step
Ready to start a provider chart review?
Begin by reviewing the treatment option and completing the secure provider chart review process.